Clinical Trials Logo

BRAF V600E Mutation Present clinical trials

View clinical trials related to BRAF V600E Mutation Present.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02097225 Active, not recruiting - Metastatic Melanoma Clinical Trials

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Start date: May 29, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that have spread to another place in the body (metastatic) or cannot be removed by surgery. Onalespib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.